Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Biotechnology

Healthcare
$20.58 -3.08%

-$0.74 today

Market cap
$302.08M
Beta
1.38
P/E (TTM)
-15.6
EPS (TTM)
-$1.49
52W Low $7.78High $34.10

Volume 0.71M

Average 0.14M

GLSI Total Non-current Liabilities

All obligations due after more than one year.

Greenwich LifeSciences, Inc.NASDAQ: GLSI

Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total non-current liabilities remains negative

Q1 FY2026 total non-current liabilities was $0, compared with $0 a year earlier.

Context

  • Total non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Total non-current liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Total Non-current Liabilities vs competitors

How GLSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Total non-current liabilities amounts to 0.0% of total assets for GLSI, versus a peer median of 48.1%.
GLSI Competitors
Total Non-current Liabilities for GLSI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SRZNSurrozen, Inc.Mar 2026$389.29M USD+294.9%+321.2%322.5%
AGENAgenus Inc.Mar 2026$165.2M USD-47.4%-13.5%88.6%
IRDOpus Genetics, Inc.Mar 2026$103.28M USD+448.1%—154.6%
SEERSeer, Inc.Mar 2026$20.41M USD-11.5%-9.4%7.5%
ONCYOncolytics Biotech Inc.Mar 2026CA$7.87M CAD+5.8%+1.7%96.4%
IMMXImmix Biopharma, Inc.Mar 2026$912.34K USD-7.9%+25.3%1.0%
HURATuHURA Biosciences, Inc.Mar 2026$447.99K USD—+189.2%1.5%
CGTXCognition Therapeutics, Inc.Mar 2026$176K USD-37.1%-56.6%0.5%
GLSIGreenwich LifeSciences, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding GLSI) —-7.9%+1.7%48.1%

Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.2M13.47M6.99M4.09M(6.74M)
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets00000
Total Current Assets27.2M13.47M6.99M4.09M(6.74M)
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets12.62K9K5.39K1.78K0
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets12.62K9K5.39K1.78K0
Total Assets27.22M13.48M6.99M4.09M(6.74M)
Account Payables0035.47K1.18M0
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities000382.2K5.55M
Total Current Liabilities385.17K262.91K294.41K1.56M5.82M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities00000
Total Liabilities385.17K262.91K294.41K1.56M2.02M
Common Stock13.15K12.85K12.85K13.15K14.3K
Retained Earnings(33.65M)(41.47M)(50.36M)(66.15M)(87.14M)
Accumulated OCI(0)0000
Other Stockholders Equity00001.79M
Minority Interest00000
Total Equity26.83M13.21M6.7M2.53M1.79M
Total Debt00000
Net Debt(27.2M)(13.47M)(6.99M)(4.09M)6.74M

Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Intrinsic Alpha fair value

Locked

Current Price

$20.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.